Liang Weiren, Hao Weiyuan, Shao Guoliang, Zheng Jiaping, Zeng Hui, Zhou Danping, Yao Hefeng
Department of Interventional Therapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Department of Endoscopy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Front Oncol. 2022 May 23;12:855909. doi: 10.3389/fonc.2022.855909. eCollection 2022.
Microwave ablation (MWA) for hepatocellular carcinomas (HCCs) in the elderly has been the subject of new research in recent years. However, there are currently no strong lines of evidence for the prognosis following MWA treatment for HCC in the elderly. Therefore, we conducted a systematic review to assess the safety and feasibility of MWA for HCC in elderly patients.
Up until August 15, 2021, a comprehensive literature search was undertaken in PubMed, Scopus, CENTRAL (Cochrane Central Register of Controlled Trials), and Google Scholar databases for all published articles. Observational studies reporting the safety and feasibility of MWA for HCC in elderly patients were included. The Newcastle-Ottawa Scale (NOS) was used to measure the quality assessment.
Our review, composed of 7 observational studies, including a total of 7,683 HCC patients, looked at the safety and feasibility of MWA for HCC in the elderly. Current lines of evidence on the risks and outcomes of MWA of HCC treatments in elderly patients are discussed.
According to our findings, elderly patients, even those with a high comorbidity index, benefited from MWA of HCC similar to younger patients. More clinical data are needed to determine selection criteria for elderly HCC patients to increase the possibility of receiving MWA as a potential lifesaving option. As such, further studies evaluating the outcomes of MWA for HCC treatment modalities in elderly patients are warranted.
https://www.crd.york.ac.uk/prospero/, identifier CRD42021273091.
近年来，老年肝细胞癌（HCC）的微波消融（MWA）成为新的研究课题。然而，目前尚无有力证据表明老年HCC患者接受MWA治疗后的预后情况。因此，我们进行了一项系统评价，以评估MWA治疗老年HCC患者的安全性和可行性。
截至2021年8月15日，在PubMed、Scopus、CENTRAL（Cochrane对照试验中心注册库）和谷歌学术数据库中对所有已发表的文章进行了全面的文献检索。纳入报告老年患者HCC的MWA安全性和可行性的观察性研究。采用纽卡斯尔-渥太华量表（NOS）进行质量评估。
我们的综述由7项观察性研究组成，共纳入7683例HCC患者，探讨了MWA治疗老年HCC患者的安全性和可行性。讨论了目前关于老年患者HCC的MWA治疗风险和结果的证据。
根据我们的研究结果，老年患者，即使是合并症指数较高的患者，与年轻患者一样，从HCC的MWA治疗中获益。需要更多的临床数据来确定老年HCC患者的选择标准，以增加接受MWA作为潜在挽救生命选择的可能性。因此，有必要进一步开展研究，评估老年患者HCC治疗方式中MWA的疗效。
